公开(公告)号：US20250003988A1

公开(公告)日：2025-01-02

申请号：US18443416

申请日：2024-02-16

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino ,  Hongwei Zhang

IPC: G01N33/68

Abstract: Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.

公开(公告)号：US20230258661A1

公开(公告)日：2023-08-17

申请号：US18147420

申请日：2022-12-28

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Hongwei Zhang

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/60 ,  G01N2333/916 ,  G01N2333/47 ,  C12Y301/02015

Abstract: Disclosed herein are methods and systems of determining whether a subject's levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in a sample collected from the subject. The methods comprise determining whether the levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in the sample, and communicating the determination on or from an instrument. The methods may be used to aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild, moderate, severe, or moderate to severe traumatic brain injury (TBI).

公开(公告)号：US20240094226A1

公开(公告)日：2024-03-21

申请号：US18509717

申请日：2023-11-15

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino ,  Hongwei Zhang

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2333/916 ,  G01N2333/948 ,  G01N2800/28 ,  G01N2800/50

Abstract: Disclosed herein are methods of determining whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject.